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Background: Genetics clearly plays a major role in the etiology of autism spectrum disorders (ASDs), but studies to
date are only beginning to characterize the causal genetic variants responsible. Until recently, studies using multiple
extended multi-generation families to identify ASD risk genes had not been undertaken.
Methods: We identified haplotypes shared among individuals with ASDs in large multiplex families, followed by
targeted DNA capture and sequencing to identify potential causal variants. We also assayed the prevalence of the
identified variants in a large ASD case/control population.
Results: We identified 584 non-conservative missense, nonsense, frameshift and splice site variants that might
predispose to autism in our high-risk families. Eleven of these variants were observed to have odds ratios greater
than 1.5 in a set of 1,541 unrelated children with autism and 5,785 controls. Three variants, in the RAB11FIP5,
ABP1, and JMJD7-PLA2G4B genes, each were observed in a single case and not in any controls. These variants
also were not seen in public sequence databases, suggesting that they may be rare causal ASD variants.
Twenty-eight additional rare variants were observed only in high-risk ASD families. Collectively, these 39 variants
identify 36 genes as ASD risk genes. Segregation of sequence variants and of copy number variants previously
detected in these families reveals a complex pattern, with only a RAB11FIP5 variant segregating to all affected
individuals in one two-generation pedigree. Some affected individuals were found to have multiple potential risk
alleles, including sequence variants and copy number variants (CNVs), suggesting that the high incidence of autism
in these families could be best explained by variants at multiple loci.
Conclusions: Our study is the first to use haplotype sharing to identify familial ASD risk loci. In total, we identified
39 variants in 36 genes that may confer a genetic risk of developing autism. The observation of 11 of these variants
in unrelated ASD cases further supports their role as ASD risk variants.
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Twin and family studies clearly demonstrate that genet-
ics plays a major role in the etiology of ASDs [1-7].
However, family-based approaches using sib-ships or nu-
clear families have not resulted in the identification of
genes or variants that explain a significant portion of the
affected population. Similarly, genetic linkage studies
have identified a number of chromosomal regions that
are thought to contain genes that predispose to ASDs,
but identification of the relevant gene(s) in these regions
has proven difficult.
More recent analyses have revealed that many of the
point mutations thought to predispose children to ASDs
were not present in either parent, and thus occurred
spontaneously in the affected individuals [8-12]. Such de
novo variants likely account for as much as 20 to 30% of
the genetic variation which results in ASDs. Additional
cases are likely due to recessive inheritance of non-
functional or hypo-functional alleles, but autosomal re-
cessive inheritance is thought to explain only about 1%
of autism cases [13,14].
In addition to single nucleotide variants and small
insertions/deletions that can be identified by DNA se-
quencing, larger deletions or duplications (copy number
variants, CNVs) have been shown to play a role in the
etiology of ASDs [15-27]. Despite the observed inherit-
ance of many ASD predisposition CNVs from an un-
affected parent, the lack of extended, multi-generation
pedigrees has precluded a comprehensive analysis of segre-
gation of putative ASD predisposition CNVs and single nu-
cleotide polymorphisms (SNPs) and the characterization of
other genetic factors necessary for their expression.
The large families available in Utah coupled with the
willingness of family members to participate in genetic
studies have resulted in the identification of a large
number of disease predisposition genes for both Men-
delian and complex diseases. The pedigrees used in this
study were part of a 70-family linkage study published
previously [28] and two smaller studies that evaluated a
single extended pedigree in this collection of families
[29,30]. In this work, we analyzed members of 26
extended multi-generational ASD families and four two-
generation multiplex ASD families by performing haplo-
type sharing analysis to identify chromosomal regions
that might harbor ASD predisposition genes. We then
used DNA capture and sequencing of all genes in shared
regions and of additional candidate autism risk genes to
identify SNPs that might predispose to ASD in these
families. These SNPs were analyzed in a large case/con-
trol study and for segregation in these families. We also
evaluated the segregation of CNVs, reported previously
[27], in these families. Consistent with earlier studies, no
single locus could account for more than a subset of the
affected individuals in any extended pedigree. In particular,multiple potential risk alleles, including in some cases
CNVs and SNPs, were identified in an extended pedigree,
suggesting that no single variant is the genetic predispos-
ition locus for all affected family members. The data pre-
sented here identify several genes that may harbor ASD
predisposition mutations, and add to the growing list of
genes that are targets for clinical DNA sequencing to aid
in the understanding of an ASD genetic diagnosis. These
data further suggest that in some individuals multiple gen-
etic variants may be necessary to elicit the observed clinical
characteristics and that for a complete understanding of ASD
genetics, both sequence variants and CNVs must be analyzed.
Methods
DNA samples
A total of 386 DNA samples from 26 extended multi-
generation and four two-generation Utah multiplex ASD
pedigrees were used in this study. Families were ascer-
tained and recruited using the Utah Population Database
(UPDB) as described [28]. Affection status was deter-
mined using the Autism Diagnostic Interview-Revised
(ADI-R) and the Autism Diagnostic Observation Schedule
(ADOS), for both the familial ASD cases and the unre-
lated ASD cases, as described previously [27]. The average
number of affected individuals in each pedigree is 7.9. The
pedigrees described here are a subset of those described
previously [28]. Pedigree details are shown in Additional
file 1: Table S1. The 55 samples used for our previous
CNV discovery were included in these families. A total of
9,000 DNA samples previously described in a case/control
study [27], including 3,000 individuals with ASD and
6,000 controls, were used to evaluate these variants in
a broader population. All samples collected for the
work described here were collected under methods ap-
proved by the University of Utah Institutional Review
Board (IRB) (University of Utah IRB#: 6042–96) or The
Children’s Hospital of Philadelphia IRB (CHOP IRB#:
IRB 06–004886). Patients and their families were re-
cruited through the University of Utah Department of
Psychiatry or The Children’s Hospital of Philadelphia
clinic or CHOP outreach clinics. Written informed
consent was obtained from the participants or their
parents using IRB approved consent forms prior to enroll-
ment in the project. There was no discrimination against
individuals or families who chose not to participate in the
study. All data were analyzed anonymously and all clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki.
SNP microarray genotyping
Affymetrix 250 K NspI SNP chip genotyping was carried
out on all 386 DNA samples using the manufacturer’s
recommended procedure. Genotypes were called by Affy-
metrix Genotyping Console software using the BRLMM
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greater than or equal to 99% were used for further ana-
lyses. SNPs demonstrating Mendelian errors also were
identified using PedCheck [32] and were excluded.Shared haplotype analysis
We performed shared haplotype analysis on each pedi-
gree to identify genomic regions that have significant
sharing among the affected individuals in that pedigree.
The HapShare algorithm [33] was used to perform
haplotype phasing based on Mendelian inheritance and
to identify shared genomic segments. The comparisons
included N out of N affected individuals, (N-1) out of N,
(N-2) out of N, (N-3) out of N, and so on (See Figure
one in reference [33]). In two-generation pedigrees, in
some cases co-segregation of haplotypes was observed in
all affected individuals analyzed, but the shared regions
were large, including up to half of a chromosome. Con-
sequently, shared regions from nuclear families were not
selected for sequencing unless they overlapped regions
observed in additional families.Custom targeted exome DNA sequencing
NimbleGen (Roche NimbleGen, Inc., Madison, WI, USA)
custom sequence capture arrays were designed to capture
2,000 base pairs upstream of the transcription start site
and all exons and exon-intron boundaries of genes within
the shared genomic segments. An additional 23 genes from
outside of our haplotype sharing regions were selected
from the literature based on their potential roles in autism
or neuronal functions (see Additional file 1: Table S2). A
total of approximately 1,800 genes were captured. Capture
and Illumina DNA sequencing were performed by the Van-
derbilt University Microarray Shared Resource facility on
DNA from 26 affected individuals from 11 families that
showed sharing of genomic segments. Short reads were
aligned to the National Center for Biotechnology Informa-
tion (NCBI) reference human genome build 36 (GRCh36/
hg18) and variants were called using the software align-
ment and variant calling methods described in Table 1
[34-36]. Potential variants detected by at least two of the






Method 1 Bowtie Maq
Method 2 MOSAIK GigaBayes
Method 3 CLC Bio Genomics
Workbench (CLC Bio Inc.)
CLC Bio Genomics Workbench
(CLC Bio Inc., Cambridge, MA, USA).Variant annotation
In silico functional analysis was carried out initially using
cSNP classifier, a preliminary program later incorporated
into VAAST [37], to classify variants as synonymous, con-
servative missense, non-conservative missense, nonsense,
frameshift, or splice site changes. Later, variants were re-
annotated using the ANNOVAR program [38]. The
KnownGene and RefSeq gene tracks from the UCSC gen-
ome browser were used to annotate functional variants,
and the LiftOver tool was used to convert human genome
build 36 (GRCh36/hg18) coordinates to human genome
build 37 (GRCh37/hg19) coordinates [39,40].
Custom microarray design and array processing
Design of the custom iSelect InfiniumTM II BeadChip
array (Illumina Inc., San Diego, CA, USA) including
probes for 2,799 putative functional candidate SNPs and
7,134 CNV probes was described previously [27]. The
custom iSelect array was processed on 3,000 case and
6,000 control samples at the Center for Applied Genom-
ics at The Children’s Hospital of Philadelphia (CHOP)
[27]. The same array was also used to analyze DNA from
196 Utah discovery cohort family members at the
University of Utah Genomics Core facility for variant
validation and analysis of SNP segregation in families.
Array data quality control
Sample QC
Subjects were withheld from SNP analysis if any of the
following were true: 1) subsequent to genotyping, the
DNA sample was of apparent poor quality, evidenced by
very low call rates (N = 134); 2) the subject was identi-
fied as a trisomy-21 (N = 51); 3) the subject was outside
of the central cluster of Caucasian subjects identified by
principal component analysis (PCA) (N = 903) [27].
Relatedness estimation further indicated that some of
the case subjects and controls were part of families with
multiple relatives represented in the data. Re-evaluation
of family structure in the sample cohorts used subse-
quently identified additional relationships. Subsequent
association tests were therefore conducted using only
one member of each known family in order to reduce
the possibility of statistical confounding due to related-
ness. For these tests, the subject selected from each fam-
ily was the individual located nearest to the median
centroid of the first two principal components. The
number of subjects removed due to relatedness was 688.
This resulted in a final sample set for association testing
comprising 7,326 subjects, of which 1,541 were cases
and 5,785 were controls.
PCA was used to avoid artifacts due to population
stratification. Principal components were calculated in
Golden Helix SNP and Variation Suite (SVS) using
default settings. All subjects were included in the
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trol (QC). Prior to calculating principal components, the
SNPs were filtered according to the following criteria:
autosomes only, call rate > 0.95, minor allele frequency
(MAF) > 0.05, linkage disequilibrium R2 < 25% for all
pairs of SNPs within a moving window of 50 SNPs. Two
thousand and eight SNPs, including those used for CNV
analysis, were used for the principal component calcula-
tions. No genotype data were available for reference
populations, as would typically be preferred for making
inferences about population stratification. However, a
self-reported ethnicity variable was available for most
subjects. A plot of the first two principal components
shows a primary central cluster of subjects, with outlier
groups extending along two axes. These roughly corres-
pond to Asian and African-American ancestry as self-
reported in the phenotype data. A simple outlier detection
algorithm was applied to stratify the subjects into two
groups representing the most probable Caucasians and
non-Caucasians. This was done by first calculating the
Cartesian distance of each subject from the median cen-
troid of the first two principal component vectors. After
determining the third quartile (Q3) and inter-quartile
range (IQR) of the distances, any subject with a distance
exceeding:
Q3þ 1:5 IQR
was determined to be outside of the main cluster, and
therefore non-Caucasian. Six hundred and eighty-two
subjects were placed in the non-Caucasian category. A
graphical representation of the results of this PCA ana-
lysis were reported previously [27].
SNP QC
Prior to association testing, SNPs were evaluated for call
rate, Hardy-Weinberg equilibrium (HWE) and allele fre-
quency. All SNPs with call rates lower than 99% were re-
moved from further analysis. No SNPs had significant
Hardy-Weinberg disequilibrium.
Laboratory confirmation of SNPs and CNVs
For molecular validation of SNPs, PCR products were
first screened by LightScanner High Resolution Melt
curve analysis (BioFire Diagnostics Inc., Salt Lake City,
UT, USA) for the presence of sequence variants. PCR
primer sequences are shown in Additional file 1: Table
S3. Any samples that gave abnormal melt profiles were
sequenced using the Sanger method at the University
Utah Sequencing Core facility to confirm the presence
of a sequence variant. For CNVs, pre- or custom-
designed TaqMan copy number assays (Applied Biosys-
tems Inc., Foster City, CA, USA) were used as described
previously [27].Protein binding assays
All glutathione S-transferase (GST)-tagged proteins were
expressed and purified as described previously [41]. To
test Rab11FIP5 binding to various Rab GTPases, purified
recombinant FIP5(490–653) or FIP5(490–653)-P652L
were incubated with glutathione beads coated with GST,
GST-Rab11a, GST-Rab4a or GST-Rab3a in the presence
of 1 μm GMP-PNP. Beads were then washed with PBS
and eluted with 1% sodium dodecyl sulphate (SDS).
Eluates were then analyzed for the presence of FIP5
(490–653) by immunoblotting with anti-Rab11FIP5 anti-
bodies. A similar assay also was used to test the ability
of Rab11FIP5 (wild-type or P652L mutant) to dimerize.
Flow cytometry analysis of transferrin recycling
To test the effect of the Rab11FIP5-P652L mutant on
endocytic recycling, the transferrin recycling assay was
used as described previously [42]. Briefly, HeLa cells ex-
pressing either wild-type FIP5-GFP or FIP5-GFP-P652L
were incubated with transferrin conjugated to Alexa488.
Cells were then washed and incubated with serum-
supplemented media for varying amounts of time. The
cell-associated (not recycled) Tf-Alexa488 was analyzed
by flow cytometry.
Results
To identify genes that predispose to ASDs in multiplex
ASD families, we took a haplotype sharing/custom DNA
capture and sequencing approach. We utilized the work-
flow outlined in Figure 1, first to identify chromosomal
regions with excessive sharing among affected individ-
uals in multiplex ASD families. We then used sequence
capture to identify potential functional sequence variants
in the genes lying in the shared regions, as well as in
additional ASD candidate genes. Finally, we evaluated
the segregation of those variants in our ASD families
and determined their prevalence in a large set of ASD
cases and a large set of controls. The details of this
process are described below.
Affymetrix 250 K SNP genotyping and haplotype sharing
SNP genotyping was carried out on 386 DNA samples
from 26 extended multi-generation and four two-
generation Utah multiplex ASD pedigrees. SNPs with no
map location were not included in the analysis. The
average call rate was 99.1% for the entire dataset.
We used the HapShare method [33] to identify gen-
omic regions that have significant sharing among the af-
fected individuals in each of the 30 pedigrees we studied.
Paternal and maternal haplotypes were determined
based on Mendelian inheritance using only informative
markers. These haplotypes then were compared among
affected individuals within each extended or nuclear
family. We selected 18 regions of haplotype sharing
Figure 1 Workflow for sequence variant discovery and analysis. Only ethnicity and gender matched, unrelated, cases and controls were
used for association testing.
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lysis. The degree of sharing that we observed among af-
fected individuals and the coordinates of the regions
selected for DNA capture and sequencing are shown in
Table 2. Two additional regions were selected for DNA
capture and sequencing based on a published linkage
analysis using an overlapping set of families [28].
Sequence capture, sequence analysis and variant
identification
We performed capture and DNA sequencing using
DNA from 26 affected individuals from 11 families that
showed the best sharing of genomic segments. These
samples included individuals from two-generation pe-
digrees that had shared haplotypes overlapping regions
identified in the extended pedigrees. Eight to nine
million 36 base short reads were obtained from each
sample. The short reads alignment against the NCBI
reference human genome build 36 revealed coverage of
86 to 97% of the designed capture area, with the average
read depth over the designed capture area of 30 to 47X.
Because 1) the capture library was constructed in a
directional manner, 2) all capture probes represented the
same DNA strand, and 3) the library was sequenced only
from one direction, some portions of exons lacked the
sequence depth of coverage that we desired. Conse-
quently, there could be additional variants (false negative
results) that we did not detect in some of the genes. ForTable 2 Chromosomal regions selected for sequencing based



















Where multiple numbers are given, multiple families shared overlapping haplotype
share the same haplotype.example no variants were identified on haplotypes that
segregate to all affected individuals in pedigree 10 on
chromosomes 2 and 14 (Additional file 2: Figure S1, A
and B, Additional file 3: Figure S2). Nonetheless, variant
calling using the three methods shown in Table 1 identified
over one million sequence variants called by at least two of
the three methods. Analysis using cSNP classifier resulted
in the detection of 2,825 putative functional candidate
SNPs, including 210 nonsense variants, 1,614 non-
conservative missense variants, 35 frameshift variants and
966 splice site variants.
We chose to design a custom microarray to evaluate
the variants that we identified by sequencing in order to
1) interrogate the entire set of candidate functional SNPs
in the discovery families for validation, and 2) to per-
form a large scale case/control study to determine if any
of the variants identified predisposition genes important
to the broad population of children with ASD (Figure 1).
Following array design and manufacture, probes for
2,413 variants were created successfully. Custom microarray
experiments on Utah discovery and CHOP case/control
samples revealed 584 out of 2,413 putative variants to
be polymorphic. The complete list of polymorphic vari-
ants is shown in Additional file 1: Table S4. The
remaining array probes did not detect a non-reference
sequence allele. These 1,829 variants thus were inter-
preted to be false positives due to the variant calling
and alignment process of single end sequence data.on haplotype sharing
(hg18) Location (hg19) Affecteds sharing haplotype
6349401 65758525-76495893 6 of 6
74296304 153930066-174588058 6 of 6
38617145 231727399-238952406 5 of 7
12685490 110121329-111202800 4 of 7
85701563 173112244-184218869 4 of 7, 4 of 4
41629142 137143104-141409692 6 of 6
861952 7415217-11895427 4 of 4, 4 of 6
1521542 36124292-41555017 4 of 7
7823133 90673308-108035897 5 of 8a
51152511 143040227-151521578 4 of 6
7788028 77595859-79263897 5 of 7
7939487 81165657-89415356 5 of 8
5661808 23842739-46592058 3 of 4, 6 of 6
3509782 93261782-104440029 4 of 4
3759484 26788694-45972192 3 of 4, 4 of 6, 5 of 8
7780513 74857552-79223012 4 of 7, 5 of 6, 3 of 4
1225971 25305250-41792557 4 of 7
7757418 49629479-58324023 5 of 6, 5 of 6
s. aIndicates a family where a ninth affected individual was later shown not to
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with autism in our case/control study using an allelic
association test. Statistical significance of each was
assessed using both Fisher’s exact test and a chi-squared
test. The allelic association test detects any significant
result regardless of the direction of the effect. Eleven
SNPs (see clustering in Additional file 4: Figure S3) were
either unique to cases or had odds ratios (minor allele)
greater than 1.5 (Table 3). We prioritized the variants
observed in our case/control study for additional work
based on an odds ratio cutoff of 1.5. We also included
variants unique to cases. We chose this approach rather
than using P values since these variants were too rare to
select based on P values, and for relatively rare diseases
odds ratios are approximately equivalent to relative risk
values. In addition, 28 SNPs were detected only in the
Utah discovery cohort and not in the CHOP cases or
controls (Table 4). We consider these 28 SNPs to be
potential ASD risk alleles because a) they are rare or
non-existent in the general population and thus could
represent ‘private mutations’, b) they may affect protein
function, and c) they segregate to one or more children
with autism in high-risk autism pedigrees. Thus, we
characterize these 39 SNPs, found in 36 different genes,
as potential autism risk variants. Each of these 39 vari-
ants was localized to our targeted regions (Table 2), and
30 of the 39 variants were predicted to be damaging by
at least one program embedded in ANNOVAR [38],
including SIFT, Polyphen2, LRT and MutationTaster.
Details of the analysis of these variants are shown in
Additional file 1: Table S5. All 39 SNPs were further
confirmed by Sanger DNA sequencing of PCR amplicons







Chi-squared P Odds rat
(Minor
allele)
G/T RAB11FIP5 chr2:73302656 2.10E-01 5.27E-02 infinite
G/C ABP1 chr7:150554592 2.10E-01 5.27E-02 infinite
T/A JMJD7-
PLA2G4B
chr15:42133295 2.10E-01 5.27E-02 infinite
C/T C7orf10 chr7:40498796 4.02E-02 3.13E-02 1.62
C/T AKAP9 chr7:91724455 6.62E-02 4.44E-02 3.76
C/T HEPACAM2 chr7:92825188 5.84E-02 3.88E-02 1.83
G/T ALX1 chr12:85674230 2.22E-02 1.49E-02 1.75
G/A AP1G2 chr14:24035159 1.66E-01 1.35E-01 1.67
G/C CLMN chr14:95679692 2.29E-01 2.23E-01 1.67
G/A MOK chr14:102749873 1.97E-01 1.55E-01 3.76
G/A OIP5 chr15:41611874 3.77E-01 2.53E-01 2.25
Het. Refers to individuals heterozygous for the indicated variant.for sequence chromatograms). The transcripts used for
variant annotation are found in Additional file 1: Table S5.
Segregation of variants in high-risk pedigrees
To determine the potential significance of variants that
we identified, we evaluated the segregation pattern of
these variants in the relevant pedigrees. We identified
potentially detrimental sequence variants in 10 of the 11
pedigrees from which individuals were selected for DNA
capture and sequencing. Several of the pedigrees segre-
gated more than one variant, indicating the complexity
of the underlying genetics in high-risk ASD pedigrees.
Moreover, many of these pedigrees also have CNVs that
were identified in our previous work [27]. Adding to
the genetic complexity, many of these CNVs also segre-
gate to affected individuals. Five families that demonstrate
these complex inheritance patterns are shown here
(Figures 2, 3, 4, 5 and 6). Five additional pedigrees with
multiple variants are shown in Additional file 7: Figure S6,
Additional file 8: Figure S7, Additional file 9: Figure S8,
Additional file 10: Figure S9, Additional file 3: Figure S9.
Pedigree 1 (Figure 2) shows a two-generation family co-
segregating a missense variant in RAB11FIP5 (Table 4).
This variant is present in the mother and segregates to all
three male affected children in the family, and not to the
unaffected female child. RAB11FIP5 has previously been
implicated as an ASD risk gene based on its disruption by
a translocation observed in a 10 year-old male child with a
diagnosis of pervasive developmental disorder not other-
wise specified (PDD-NOS) [43]. The variant detected in
pedigree 1 results in a P652L substitution. Proline is con-
served at this residue in all of the mammalian RAB11FIP5


















N/A N/A 1 0 1,540 5,785 P652H
N/A N/A 1 0 1,540 5,785 R345P
N/A N/A 1 0 1,540 5,785 splice site
1.04 2.53 28 65 1,513 5,720 R288W,
splice site
0.94 15.03 4 4 1,537 5,781 R3233C
1.02 3.27 17 35 1,524 5,750 G398R
1.11 2.77 27 58 1,514 5,727 R64L
0.85 3.30 12 27 1,529 5,757 R99C
0.73 3.84 8 18 1,533 5,767 P158A
0.53 26.67 2 2 1,539 5,783 Q22X
0.54 9.44 3 5 1,538 5,780 S165F
Figure 2 Co-segregation of a RAB11FIP5 variant. Two-generation pedigree (pedigree 1) with three male siblings affected with autism. Sequence
variants identified in the family are shown in the black boxes. Open boxes - unaffected male family members; open circles - unaffected female family
members; filled boxes - affected male family members. Odds ratios for the variants observed in the case/control study are shown. Variants with no
odds ratio were observed only in high-risk families. All family members were tested for all variants.
Table 4 Sequence variants observed only in high-risk ASD families
Variant
(Ref/Obs)









G/A RAB11FIP5 chr2:73302656 2-Generation 3 3 P652L
C/G AUP1 chr2:74756328 Extended 5 1 R90S
T/C SCN3A chr2:165946964 Extended 6 1 E1851G
T/C ATP11B chr3:182583394 Extended 9 2 S451P
A/G KLHL6 chr3:183226296 2-Generation 5 4 F154L, splicing
C/T AKAP9 chr7:91736684 Extended 7 1 R3832C 0.000154
G/C PDK4 chr7:95215047 2-Generation 6 3 S381X
C/G RELN chr7:103214555 Extended 7 1 D1499H 0.000231
G/A DCAF11 chr14:24590630 2-Generation 3 2 G435R
G/A RNF31 chr14:24617687 Extended 9 1 splicing
G/C IRF9 chr14:24634003 Extended 9 1 R277T
G/A SDR39U1 chr14:24909513 2-Generation 6 2 P220S
T/A PRKD1 chr14:30095731 2-Generation 3 2 D586V
C/T SEC23A chr14:39545251 2-Generation 3 1 G292D
G/A ITPK1 chr14:93418316 2-Generation 5 2 P238L
G/A CCDC85C chr14:99988547 Extended 9 1 R300W
A/G C14orf2 chr14:104381450 2-Generation 6 5 I26T
G/T TRPM1 chr15:31329966 Extended 5 1 T857K
T/C FMN1 chr15:33359761 Extended 9 3 R109G
G/T PGBD4 chr15:34395847 Extended 9 4 G372V 0.000231
C/T JMJD7 chr15:42129054 Extended 9 4 R260C 0.00068
C/T CASC4 chr15:44620915 Extended 5 1 R139X
G/C SPATA5L1 chr15:45695534 2-Generation 5 3 D303H
C/G PYGO1 chr15:55839207 Extended 7 1 G92R
C/G PRTG chr15:55916638 Extended 9 2 A999P
G/A NUDT7 chr16:77756514 Extended 9 4 R12K, splicing
G/A DEFB124 chr20:30053379 Extended 7 4 P49L 0.000154
A/G EPB41L1 chr20:34809850 Extended 9 1 D733G
Matsunami et al. Molecular Autism 2014, 5:5 Page 8 of 18
http://www.molecularautism.com/content/5/1/5
Figure 3 Segregation of C14orf2 variant. Two-generation pedigree (pedigree 2), with three affected female and two affected male siblings as
well as an affected male half-sibling. The C14orf2 variant segregates to five of six affected children. Pedigree symbols are described in the legend
for Figure 2. Sequence variants identified in the family are shown in the black boxes. A CNV found in the affected half-sibling [27] is shown in the
red box. Odds ratios for variants observed in the case/control study are shown in parentheses. Variants with no odds ratio were observed only in
high-risk families. All family members were tested for all variants unless no DNA was available. Individuals with no available DNA are indicated.
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variant, was detected in our case/control study (Table 3)
using our custom microarray. Neither the P652L substitu-
tion nor the P652H substitution was observed in the
ESP6500, 1,000 genomes project or dbSNP137 databases
(Additional file 1: Table S5). Each of these variants was
confirmed by Sanger sequencing (See Additional file 5:
Figure S4, Additional file 6: Figure S5 for chromato-
grams). An additional affected individual of non-European
descent, and thus not included in the case/control study,
also carried the P652H variant (data not shown). The
presence of the P652H variant in an additional individual
with autism and not in any controls further supports the
likelihood of variants in RAB11FIP5 contributing to aut-
ism risk.
Pedigree 2 (Figure 3) is a two-generation family with
six affected individuals from two fathers. In this pedi-
gree, five of the six affected individuals inherit a variant
resulting in an I26T substitution in C14orf2. Two add-
itional sequence variants, one each in the PDK4 andFigure 4 Segregation of KLHL6, SPATA5L1, and ITPK1 variants. Two-gene
variants identified in the family are shown in the black boxes. Pedigree symbo
were observed only in high-risk families. All family members were tested for aSDR39U1 genes, segregate to three and two affected indi-
viduals respectively. In addition, a CNV gain (OR = 3.37)
described previously [27] is present in one affected indi-
vidual. The C14orf2 and PDK4 variants were maternally
inherited, while the C7orf10 and the CNV were either of
paternal origin or occurred as de novo variants. Of the var-
iants detected in this family, only the C7orf10 variant was
observed in our case/control study. However, this variant
had an odds ratio of 1.62 (95% confidence interval 1.04 to
2.53), suggesting the possibility for a role in autism predis-
position in the general population.
Pedigree 3 (Figure 4) also is a two-generation family,
with five male children affected with autism. In this
pedigree, four of the five affected individuals exhibit ma-
ternal inheritance of an F154L variant in the KLHL6
gene. This A/G nucleotide variant also is found at the
first nucleotide of an exon and thus also may affect spli-
cing of the KLHL6 primary transcript. In addition to this
variant, three of the five offspring have a paternally inher-
ited D303H missense variant in the SPATA5L1 gene whileration pedigree (pedigree 3), with five affected male siblings. Sequence
ls are described in the legend for Figure 2. Variants with no odds ratio
ll variants.
Figure 5 Segregation of DEFB124 variant in a multi-generation pedigree. Pedigree 4 has seven children affected with autism. Links between
this pedigree and other high-risk autism pedigrees are indicated by blue boxes. Sequence variants identified in the family are shown in the black
boxes. CNVs inherited by two individuals [27] are shown in red boxes. Pedigree symbols are described in the legend for Figure 2. Odds ratios for
the variants observed in the case/control study are shown in parentheses. Variants with no odds ratio were observed only in high-risk families. All
family members were tested for all variants unless no DNA was available. Individuals with no available DNA are indicated.
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in the ITPK1 gene. One affected child does not inherit any
of these variants. Of interest, none of the variants ob-
served in this small family were observed in any cases or
controls in our population study, demonstrating that they
are not common autism predisposition loci.
Pedigree 4 (Figure 5) is a six generation family with an
ancestor common to all seven male children that are af-
fected with autism. These children all are in the fifth or
sixth generations of the pedigree. Linkage analysis was
performed previously on this family using Affymetrix
10 K SNP genotype data [29,30], and three regions of
significant linkage were identified. These include 3q13.2-
q13.31, 3q26.31-q27.3, and 20q11.21-q13.12. These three
regions also were identified by haplotype sharing in this
study (Figure 5, see Additional file 2: Figure S1C for
chromosome 20 haplotype sharing). Four of the seven
affected individuals in this family share a P49L variant
that is the result of an A/G transition in the DEFB124
gene on chromosome 20q11.21, consistent with the
haplotype sharing that we observed (Additional file 2:
Figure S1c) and with the published linkage result. This
variant was not observed in cases or controls in ourpopulation study. One affected individual in this pedi-
gree does not share the DEFB124 variant, but instead
has a chromosome 3q gain CNV, inherited from his
father, that had an odds ratio of 3.74 in our previous
study [27]. The elevated odds ratio suggests that this
CNV is an autism risk locus.
Two additional affected individuals in pedigree 4 do
not carry any variant that we detected in our families.
However, as indicated in Figure 5, each of these two in-
dividuals is descended from a marry-in spouse with a
strong family history of autism, suggesting the possibility
of additional undetected variants.
Finally, one affected individual who carries the DEFB124
variant carries variants in the HEPACAM2 gene (odds ra-
tio 1.83 in our population study, Table 3), the AP1G2 gene
(odds ratio 1.67, Table 3), the PYGO1 gene and the RELN
gene. Neither the RELN variant nor the PYGO1 variant
was observed in the case/control study (Table 4). Interest-
ingly, a recent unpublished clinical case identified a het-
erozygous deletion involving 15 exons of the RELN gene
in a patient diagnosed with autism and behavior/conduct
disorder (Rena Vanzo, personal communication). Homo-
zygous or compound heterozygous mutations in RELN
Figure 6 Segregation of multiple variants including a sequence variant in AKAP9 and a copy number variant in NRXN1 in a
multi-generation pedigree. Pedigree 5 has nine children affected with autism. A link between this pedigree and another high-risk autism
pedigree is indicated by the blue box. Sequence variants identified in the family are shown in the black boxes. CNVs identified in four individuals
[27] are shown in red boxes. Pedigree symbols are described in the legend for Figure 2. Odds ratios for the variants observed in the case/control
study are shown in parentheses. Variants with no odds ratio were observed only in high-risk families. All family members were tested for all
variants unless no DNA was available. Individuals with no available DNA are indicated.
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deletion is the first description of an individual with a de-
velopmental phenotype that may be due to haploinsuffi-
ciency at this locus.
Pedigree 5 (Figure 6) is a four-generation family with nine
individuals affected with autism (seven male, two female).
Two variants are of particular interest in this family. The
first is a CNV including the 5′-flanking region of the
NRXN1 gene. This CNV is inherited from a father who
marries into the family in the second generation. This CNV
segregates to three of the four descendants of this individ-
ual who are diagnosed with autism. An overlapping NRXN1
CNV was shown in our previous work to have an odds ra-
tio of 14.96 [27], consistent with other publications suggest-
ing a role for NRXN1 variants in autism, as well as other
neurological disorders [46-48]. However, that CNV was
shown to extend into the coding region of NRXN1, while
TaqMan CNV analysis demonstrates that the CNV inpedigree 5 did not (data not shown). Thus, the significance
of the NRXN1 CNV observed in this family is uncertain.
A second variant identified in this family, found on a
haplotype shared by all five affected individuals in two
branches of the family (Additional file 2: Figure S1c), is a
C/T transition in the AKAP9 gene that results in an
R3233C missense substitution. Note that none of the
individuals in these two branches of the family carry the
NRXN1 CNV. The AKAP9 variant was observed in
4/1541 cases and 4/5785 controls in our population study
(odds ratio of 3.76, 95% confidence interval 0.94 to 15.03)
(Table 3). A second missense variant in the AKAP9 gene
was observed in a single affected individual in a nuclear
family (pedigree 6, Additional file 7: Figure S6). This sec-
ond AKAP9 variant was not observed in the case/control
study (Table 4). The AKAP family of proteins has been
suggested to connect different biological pathways that are
involved in nervous system development [49].
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inherited by multiple children affected with autism. One
branch of the pedigree segregates a G/C transversion in
the CLMN gene that results in a P158A missense substi-
tution. This variant yielded an odds ratio of 1.67 (95%
confidence interval 0.73 to 3.84) in our case/control
study, suggesting that it is an ASD risk allele. A variant
in the ABP1 gene, also the result of a G/C transversion
and resulting in an R345P missense substitution, was ob-
served in two affected individuals in a single branch of
the family. This variant was maternally inherited and not
seen elsewhere in the pedigree. However, this variant
was observed in 1/1,541 cases and 0/5,785 controls in
our population study (Table 3) and was not observed in
the ESP6500, 1,000 Genomes, or dbSNP137 databases
(Additional file 1: Table S5), indicating that it may be a
very rare ASD risk variant. Finally, a G/T transversion in
the ALX1 gene that results in an R64L missense substi-
tution was paternally inherited by a single individual. This
variant also was seen in pedigree 7 (Additional file 8:
Figure S7) and was observed multiple times in our
population study (27/1,541 cases and 58/5,785 controls)
yielding an odds ratio of 1.75 (95% confidence interval
1.11 to 2.77) (Table 3). Expression of this gene also may
be increased by a downstream balanced translocation in
a family with mental retardation, language delay and
microcephaly that segregate with the translocation [50].
Pedigrees 8 to 10 are shown in Additional file 9:
Figure S8, Additional file 10: Figure S9, Additional file
3: Figure S2. One of these pedigrees, pedigree 10, car-
ried two haplotypes (chromosomes 2 and 14) segregat-
ing to all six affected individuals (Additional file 2:
Figure S1a-b). Sequencing of the genes encompassed by
these regions did not identify potential causal variants.
This could be due to poor sequence coverage of some
portions of the genes. However, sequencing of affected
individuals in these families did result in the identifica-
tion of variants that could be autism risk alleles. One of
these variants, a G/A transition that result in a Q22X
change in the MOK gene observed in a single affected
individual and inherited from her father, is interesting,
as it was observed in our population study and yielded
an odds ratio of 3.76 (95% confidence interval 0.53 to
26.67) (Table 3). Other variants in pedigrees 8 to 10
(Additional file 9: Figure S8, Additional file 10: Figure
S9, Additional file 3: Figure S2), including some only
seen in Utah families and others seen in both families
and in our population study also were identified. These
variants are included in Table 3 and Table 4.
Functional analysis of RAB11FIP5
To uncover the functional consequences of the Rab11FIP5-
P652L variant we evaluated binding of Rab11FIP5 to Rab11.
Rab11 is a small monomeric GTPase that mediatesRab11FIP5 recruitment to endocytic membranes and is
required for Rab11FIP5 function [41]. As shown in
Additional file 11: Figure S10A, the P652L substitution
did not affect Rab11FIP5 binding to Rab11, nor did it
affect its specificity toward the Rab11 GTPase. It was
previously shown that Rab11FIP5 forms homodimers
and that its ability to dimerize is also required for Rab11-
FIP5 cellular functions [41]. Thus, we tested the effect of
P652L substitution on Rab11FIP5 ability to dimerize. As
shown in Additional file 11: Figure S10B, the Rab11FIP5-
P652L mutant was still able to form dimers. Consistent
with in vitro binding data, FIP5-GFP-P652L endocytic
localization in HeLa cells was also not affected (Additional
file 11: Figure S10B-E).
It is now well established that Rab11FIP5 functions by
regulating endocytic recycling [51]. To that end, we next
tested whether Rab11FIP5-P652L has an effect on recyc-
ling of transferrin receptors in HeLa cells and found that
the P652L substitution did not alter recycling (Additional
file 11: Figure S10H). Thus, so far we were unable to find
any functional consequences of Rab11FIP5-P652L substi-
tution, suggesting that core Rab11FIP5 properties are not
affected. Further studies will be needed to uncover the
kinetic or binding defects of Rab11FIP5 variants, espe-
cially within the context of neuronal cells.
Discussion
Numerous studies have implicated genetics in the eti-
ology of ASDs, and recent results have implicated hun-
dreds of genes and chromosomal regions as candidate
ASD predisposition loci. These include chromosomal re-
arrangements as well as sequence variants. None of
these candidates accounts for more than a small portion
of ASD cases, and it is clear, based on the apparent com-
plexity of autism genetics, that many genes are still un-
discovered. In multiplex ASD pedigrees, it has been
suggested that inherited genetic variants are more likely
to be responsible, while in simplex families de novo vari-
ants may be more important [8,16].
We used a discovery/validation strategy based on identi-
fying inherited genetic variants in two- to nine-generation
ASD families, followed by a case/control analysis of those
variants in DNA samples from unrelated children with aut-
ism and children with normal development, to identify pu-
tative familial ASD predisposition genes. Using haplotype
analysis we identified shared genomic segments within the
families, and used DNA sequencing and CNV analysis to
identify potential causal mutations on those haplotypes. We
also followed this with a large case/control study to deter-
mine if any of the variants we identified might play a role in
the general population of individuals with ASD.
We showed previously that identification of CNVs in a
family-based discovery cohort could identify copy num-
ber variants relevant to the general ASD population
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family-based identification of DNA sequence variants,
and also follow up on our CNV analysis by providing
information regarding segregation of some of these
CNVs in our high-risk ASD families.
We identified 39 SNPs that are likely to affect protein
function that have segregation patterns and ASD case
allele frequencies suggestive of a role in ASD predispo-
sition. Thirty-one of these variants result in non-
conservative amino acid substitutions, five are predicted
to affect splicing (three of these are predicted to affect
both splicing and protein coding), and three introduce
premature termination codons. Two variants were
identified in the AKAP9 gene and the JMJD7 gene (or
the JMJD7-PLA2G4B fusion gene), and two different
variants were identified that affect the same amino acid
residue in the RAB11FIP5 gene; so collectively, these
SNPs identify 36 potential ASD risk genes.
With the exception of two-generation families, and
consistent with our haplotype sharing results, no se-
quence variants or CNVs implicated as ASD predispos-
ition loci segregate to all affected individuals in a
pedigree. This is consistent with previous genetic stud-
ies, which to date have been unable to demonstrate
segregation of a single ASD risk locus in an extended
family (for example see [52]). In our pedigree 5
(Figure 6), two independent risk variants, a single
nucleotide variant in AKAP9 and a deletion CNV in or
near NRXN1, segregate to different branches of the
family. Other risk variants also are found in individuals
with ASD in this family, including two sequence variants
with odds ratios greater than 1.5 in our population
study. These results suggest that even in extended
families that might be predicted to be segregating a
single risk allele with reduced penetrance, multiple risk
alleles in different ASD predisposition loci may be
necessary. The results further suggest that use of specific
inheritance models when evaluating autism genetics in
large families should be approached with caution. Further,
given our sequencing results and CNVs, the data suggest
that a two-pronged approach, involving both DNA sequen-
cing and microarray-based CNV analysis, may be necessary
for a complete genetic diagnosis of children with ASDs.Table 5 Biological functions/pathways of genes with variants
Function Gene names
Previously associated with autism TRPM1, RAB11FIP5, AKAP9, SCN
Previously associated with neurological
disorder (other than autism)
RELN (autosomal recessive liss
CCDC85C (seizures), EPB41L1 (
Neural function ITPK1, CLMN, PRTG
Mitochondrial function PLA2G4B, c7orf10, PDK4, C14or
Inflammatory response/Immune function DEFB124, BPI, RNF31, IRF9Eleven of the putative autism risk variants that we
identified in our high-risk families are further supported
by data from our case/control study. Three of these vari-
ants each were seen in a single ASD case (out of 1,541
total cases) and in none of 5,785 controls. Familial vari-
ants that we detected in eight additional genes are more
common in ASD cases than in controls, and each has an
odds ratio greater than 1.5. Although these variants are
rare (all have frequencies of < 0.01 in our case/control
study), their identification in affected individuals in our
ASD families and their increased prevalence in unrelated
affected individuals support their role as potential ASD
risk loci.
Several intriguing observations resulted from an exten-
sive literature review of the functions and mechanistic
actions of each of these 36 genes and their encoded pro-
teins. A number of the genes have been previously
linked to autism or other neurological disorders or have
known neurological functions (Table 5) (11 out of 36
genes, or 31%). The functions of several other genes be-
long to pathways often cited as having relevance to
autism. These include genes encoding proteins with im-
munological functions (inflammatory response), and
genes encoding proteins important for energy metabol-
ism and mitochondrial function. These groups account
for 19 of the 36 genes on the list (53%). Other genes
have as yet unexplored functions, can only be linked to
functions based on sequence similarity, or have scattered
roles in many other cellular or organismal processes,
such as cell cycle control, angiogenesis, protein degra-
dation, or metalloproteinase activity.
The incidence/prevalence of autism has been reported
to be as high as 1 in 38 children [68], while the estimated
prevalence in the US is reported to be approximately 1 in
88 [69]. Multiple factors, including genetic, epigenetic and
environmental, are thought to be necessary for autism de-
velopment. As with previous work involving familial aut-
ism, we found that no single gene variant described here
can account for every case of autism in our pedigrees. This
may reasonably be expected of a multigenic disorder with
high prevalence in the population. It also is consistent
with the high likelihood that autism represents a number
of different conditions, at least at the genetic level, allfound in children with ASDs
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eral variants that we identified, however, represent excel-
lent candidates for significant risk factors for autism based
on their known functions and the currently understood
molecular pathways involved in autism. We discuss the
most compelling cases below.
RAB11FIP5
RAB11FIP5 is a member of a family of scaffolding pro-
teins for the RAS GTPase, Rab11. Specifically, RAB11-
FIP5 has been characterized as a key player in apical
endosome recycling, plasma membrane recycling and
transcytosis [70,71]. We identified a P652L variant in
three affected siblings in a family of six members, in
which the mother is an unaffected P652L carrier. An
additional variant resulting in a P652H substitution also
was detected in 1/1,541 Caucasian ASD cases and 0/
5,785 Caucasian children with normal development
(Table 3). These variants modify a conserved proline
within the C-terminus of RAB11FIP5.
Heterozygous disruption of RAB11FIP5 was observed
previously in a ten year old boy with a balanced trans-
location (46, XY, t(2;9)(p13;p24)) that disrupts only the
RAB11FIP5 gene [43]. This individual has a clinical diag-
nosis of PDD-NOS, an autism spectrum disorder. This
translocation led the authors to suggest that haploinsuf-
ficiency of RAB11FIP5 contributes to the subject’s ASD.
RAB11FIP5 works closely in conjunction with RAB11,
and its presence has been detected in both presynaptic
and post-synaptic densities where Rab11 plays a key role
in determining synaptic strength in long-term depression
[72], regulates norepinephrine transporter trafficking [73],
carries out synaptic glutamate receptor recycling [74], and
regulates dendritic branching in response to BDNF
[75,76]. All of these functions have been suggested to be
significant contributors to the etiology of ASDs [77,78]
and further support the role of mutations in RAB11FIP5
as ASD risk alleles.
AKAP9
AKAP9 is a member of a family of over 50 proteins that
serve as scaffolding partners for PKA, its effectors, and
phosphorylation targets. AKAP9, also known as Yotiao,
is chiefly expressed in the heart and brain, where the
encoded protein serves as a scaffold for PKA, protein
phosphatase I, NMDA receptors, the heart potassium
channel subunit KCNQ1, IP3R1, and specific isoforms of
adenylyl cyclase [79-83]. The subcellular localization and
assembly of these multimeric protein scaffolds, mediated
by AKAPs, are thought to be essential for function, since
disruption of the interaction between the AKAP and its
effectors leads to a loss of activity. In the case of KCNQ1,
loss of interaction between AKAP9 and KCNQ1 leads to a
potentially fatal heart condition, long-QT syndrome,which also arises in cases with loss of function mutations
in KCNQ1 itself [84].
We identified two variants in the AKAP9 gene. These
variants result in R3233C and R3832C substitutions in
the encoded protein. These two variants were coincident
with autism and were found in two unrelated extended
ASD pedigrees (Figure 6, Additional file 7: Figure S6).
The R3233C variant was additionally found in our
case/control study. A recent meta-study of the genes
identified from the five major autism GWAS studies and
autism candidate genes arising from alternative method-
ologies, such as large scale CNV studies, placed AKAPS as
a central, integral gene family linking many of the path-
ways identified by bioinformatics [49]. Given its role in lo-
calizing PKA, adenylyl cyclase isoforms and NMDAR in
the postsynaptic scaffold, AKAP9 represents a protein
that, like its better-characterized counterpart AKAP5,
could function in synaptic transmission and plasticity, glu-
tamatergic receptor function regulation and recycling, and
dendritic spine morphology [85].
It is notable that two of the genes (MOK, TRPM1)
containing potential ASD risk alleles were partially or
completely encompassed by risk CNVs observed in our
previous study [27]. This suggests that the same genes
may be affected by different genetic mechanisms with
the same or similar phenotypic result. The CNVs con-
taining these genes were both copy number losses. The
MOK sequence variant described here was a nonsense
change, while the TRPM1 variant was a missense
change. These results are consistent with the MOK and
TRPM1 effects being due to haploinsufficiency at these
two loci.
Our data demonstrate the complex nature of autism
genetics. Although the heritability for autism is quite
high, our data show that numerous genetic variants may
confer risk to ASD even in a single family. This finding
is consistent with the results of a whole genome sequen-
cing study that used both a recessive model and model
independent analyses to identify several potential ASD
risk variants in an ASD family with two affected individ-
uals [86]. Consistent with the large number of potential
ASD risk genes identified to date, none of the genes
identified in this single multiplex ASD family overlapped
with the genes identified in our study. Our study adds to
this complexity by identifying sequence variants in re-
gions of haplotype sharing in 30 high-risk ASD families
of two to six generations. Our data further demonstrate
that in very large multi-generation families, the likeli-
hood of additional risk variants entering the family from
individuals who marry into the pedigree is high. These
results are consistent with the prevalence of autism in
the population and the high heritability for autism seen
in numerous studies. Future studies will be necessary to
characterize the biological roles that the variants we
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prise ASD.Conclusions
Our study is the first to use an empirical approach to iden-
tify shared genomic segments, followed by sequence variant
detection, to identify potential ASD risk variants in a large
set of autism families. We identified 39 DNA sequence var-
iants in 36 genes that may represent ASD risk genes. Eleven
of these variants may also be risk variants in unrelated ASD
cases, as they were shown to have odds ratios greater than
1.5 in a large ASD case/control population. Twenty-eight
of these variants were observed only in high-risk ASD fam-
ilies in our study. These very rare sequence changes also
may identify additional ASD risk genes. Segregation pat-
terns demonstrate that in multi-generation ASD families,
multiple genetic variants, including CNV and SNP risk vari-
ants, may contribute to ASD risk.Additional files
Additional file 1: Table S1. Pedigree structure. Table S2. Literature
ASD risk genes sequenced. Table S3. Primers for variant amplification
and sequencing. Table S4 List of all confirmed variants. Table S5. Analysis
of potential risk variants.
Additional file 2: Figure S1. Haplotype sharing in high-risk autism
pedigrees. The figures show a graphic representation of haplotype
sharing among affected individuals in a pedigree, created using the
HapShare program. The X-axis represents chromosomal coordinates for
the designated chromosomes. The Y-axis represents various combinations
of haplotype sharing among affected individuals in the pedigree, listed
arbitrarily by iteration number. The lowest value on the Y-axis represent
sharing among all N affected individuals in the pedigree, and where all
N individuals share, there is only one possible combination. With lower
degrees of sharing there are more possibilities. For example, in pedigree
10 with six affected individuals, there is only one possible way for all six
to share the same haplotype. Where only five of six share the haplotype,
there are six different ways to get this result, with each of the six affected
individuals being excluded from sharing in each of the six iterations
shown. Red indicates sharing among N out of N affected individuals in
the pedigree, with other colors representing lower degrees of sharing.
Panel a) two regions of chromosome 2 shared by all six affected individuals
in pedigree 10; panel b) sharing among all six affected individuals in
pedigree 10 of a chromosome 14 region; panel c) sharing among five
of eight affected individuals on chromosome 7 in pedigree 5 and
sharing among four of seven affected individuals on chromosome 20 in
pedigree 4. The variants found on these haplotypes are indicated by the
gene names in the figure. Note that the chromosome 7 region identified in
pedigree 5 as being shared among eight affected individuals was later
shown not to be shared by an additional affected family member, resulting
in a final count of sharing among five of nine affected individuals.
Additional file 3: Figure S2. Segregation of sequence variants in
SCN3A and OIP5 and CNVs involving LINGO2 in pedigree 10. Pedigree 10
has 6 affected male siblings. The female sibling in the lowest generation
has trisomy 21 and includes some features of autism. The LINGO2 loss
CNV was shown to have an odds ratio of 3.74 in our case/control study,
while the LINGO2 gain CNV did not have a clinically relevant odds ratio in
the broad ASD population. The SCN3A sequence variant was not
observed in our case/control study while the OIP5 variant yielded an odds
ratio of 2.25. Pedigree symbols are described in the legend for Figure 2.
Sequence variants identified in the family are shown in the black boxes. All
family members with DNA available were tested for all variants.Additional file 4: Figure S3. SNP genotype clusters. Genotype clusters
for all SNPs observed in the case/control study (Table 3) are shown.
Additional file 5: Figure S4. Sanger sequence confirmation of variants
in the RAB11FIP5, AUP1, SCN3A, ATP11B, KLHL6, C7orf10, AKAP9, HEPACAM2,
PDK4, RELN, ABP1, ALX1, AP1G2, DCAF11, RNF31, IRF9, SDR39U1 and PRKD1
genes. Heterozygous positions are indicated by the blue line in the
center of each panel.
Additional file 6: Figure S5. Sanger sequence confirmation of variants
in the SEC23A, ITPK1, CLMN, CCDC85C, MOK, C14orf2, TRPM1, FMN1, PGBD4,
OIP5, JMJD7, JMJD7-PLA2G4B, CASC4, SPATA5L1, PYGO1, PRTG, NUDT7,
DEFB124 and EPB41L1 genes. Heterozygous positions are indicated by
the blue line in the center of each panel.
Additional file 7: Figure S6. Segregation of a second AKAP9 variant in
a small pedigree. Pedigree 6 has a single affected child. Pedigree symbols
are described in the legend for Figure 2. A link between this pedigree and
other high-risk autism pedigrees is indicated by blue boxes. Sequence
variants identified in the family are shown in the black boxes. Odds ratios
for the variants observed in the case/control study are shown in
parentheses. Variants with no odds ratio were observed only in high-risk
families. All family members were tested for all variants unless no DNA was
available. Individuals with no available DNA are indicated.
Additional file 8: Figure S7. Segregation of an ALX1 variant in a small
two-generation pedigree. Pedigree 6 has two siblings affected with
autism. A single ALX1 variant is shared by both siblings. A link between
this pedigree and another high-risk autism pedigree is indicated by the
blue box. Pedigree symbols are described in the legend for Figure 2.
Sequence variants identified in the family are shown in the black
boxes. Odds ratios for the variants observed in the case/control
study are shown in parentheses. Variants with no odds ratio were
observed only in high-risk families. All family members were tested
for all variants.
Additional file 9: Figure S8. Multigeneration pedigree with multiple
sequence variants and overlapping loss and gain copy number variants.
Pedigree 8 has 5 affected male children. Potential causal variants in this
family do not segregate to more than one affected individual. CNVs
identified in 4 individuals [27] are shown in red boxes. Pedigree symbols
are described in the legend for Figure 2. Sequence variants identified in
the family are shown in the black boxes. Odds ratios for the variants
observed in the case/control study are shown in parentheses. Variants
with no odds ratio were observed only in high-risk families. All family
members were tested for all variants unless no DNA was available.
Individuals with no available DNA are indicated.
Additional file 10: Figure S9. Segregation of two sequence variants in
a two-generation pedigree. Pedigree 9 has three affected female siblings.
Pedigree symbols are described in the legend for Figure 2. Sequence
variants identified in the family are shown in the black boxes. All family
members were tested for all variants.
Additional file 11: Figure S10. Effects of RAB11FIP5 P652L on RAB11
binding. (A) Wild- type of P652L mutant FIP5(490–653) was incubated
with either various GST-tagged Rabs or GST-tagged FIPs. Beads were then
washed and bound FIP5(490–653) eluted with 1% SDS. Eluates were
then analyzed by immunoblotting with anti-Rab11FIP5 antibodies. (B-G)
HeLa cells were transduced with either wild-type FIP5-GFP (A and D) or
FIP5-GFP-P652L (E and G). Cells were then fixed and stained with
anti-transferrin receptor antibodies (C, D, F and G). D and E are merged
images, with yellow representing the extent of overlap between Rab11-
FIP5 and transferrin receptor. (H) HeLa cells expressing either FIP5-GFP or
FIP5-GFP-P652L were incubated with 1 μg/ml of transferrin-Alexa488. Cells
were then washed and incubated in serum-supplemented media varying
amount of time. Cell-associated (not recycled) transferrin-Alexa488 was
measured using flow cytometry. Data shown are the means of two
independent experiments.
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